← All indications
Death, Sudden
The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.
Subtype terms (3)
More specific conditions that are subtypes of Death, Sudden in the MeSH hierarchy.
- Death, Sudden, Cardiac
35 drugs (29 approved, 6 experimental)
- Sudden Infant Death
2 drugs (1 approved, 1 experimental)
- Sudden Unexpected Death in Epilepsy
5 drugs (4 approved, 1 experimental)
Drugs by status
Phase 3 trials (2)
Phase 2 trials (1)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (40)
- GlaxoSmithKline
- National Heart, Lung, and Blood Institute (NHLBI)
- Atlantic Health System
- Baylor University
- Boston University
- Harvard University
- Dartmouth University
- Duke University
- Emory University
- Geisinger Clinic
- University of Washington
- Henry Ford Health System
- Maimonides Medical Center
- Northwell Health
- Northwestern University
- Rhode Island Hospital
- Rutgers University
- University of Nebraska
- University of Rochester
- University of South Carolina
- University of Southern California
- State University of New York
- University of California, Berkeley
- University of California, Davis
- University of California, San Francisco
- University of Utah
- Icahn School of Medicine at Mount Sinai
- University of Minnesota
- Rush University
- University of Montreal
- +10 more
Organization Involved with Phase 2 Indications (5)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (1)